Figure 6.

OAd-NIS imaging and tumor control in human Panc 1 xenografts

(A) Representative images of SPECT/CT with ^99mTc in Panc1 xenografts demonstrating superiority of imaging facilitated by Cox2-NIS-ADP(–). A replication-deficient AdCMV-NIS (employed in a phase I clinical trial for prostate cancer) and a WT replication WT-NIS-ADP(+) were used as control vectors. (B) Histologic sections from tumors 28 days after low dose infection stained for NIS and Ad-hexon showing improved NIS expression after Cox2-NIS-ADP(–) (20× magnification). (C) Xenograft growth curves. Error bars represent standard deviation. All virus-injected tumors were significantly smaller than control after both high and low titer injections (p < 0.01 for all comparisons). Tumor growth after Cox2-NIS-ADP(+) and Cox2-NIS-ADP(–) injection were statistically equivalent (high dose: p = 0.971; low dose: p = 0.571).